title: Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography.
abstract: OBJECTIVE
  To evaluate the usefulness of Doppler parameters in the differentiation between the two types of amiodarone-associated thyrotoxicosis (AAT).
  
  
  METHODS
  One hundred thirty-seven individuals were selected at our institution. They were divided into four groups: 84 normal subjects (N), 30 euthyroids taking amiodarone (A), 14 AAT type 1 patients (AAT1), and nine AAT type 2 patients (AAT2). Each AAT type was classified according to (131)I uptake and clinical outcome. Blindly, the resistance and pulsatility indexes (RI, PI), systolic peak velocity, and color pixel density (CPD) were calculated.
  
  
  RESULTS
  AAT1 had greater CPD than AAT2 (P = 0.02). The latter group had similar vascularization to the N and A groups (P = 0.45). The area under the receiver operating characteristic (ROC) curve showed that systolic peak velocity in the inferior thyroid arteries and CPD were the best parameters in the differentiation between AAT type 1 and AAT type 2 (Az = 0.83 and 0.84, respectively). Impedance indexes were useless.
  
  
  CONCLUSIONS
  Our results demonstrate that objective tests such as systolic peak velocities in the thyroid arteries and CPD are reliable parameters for differentiating between the two types of AAT.
authors: Instituto de Radiologia and Central Laboratory Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. tamacedo@hotmail.com
authors: T A A
authors: TA
authors: Macedo
authors: M C
authors: MC
authors: Chammas
authors: P T
authors: PT
authors: Jorge
authors: L P
authors: LP
authors: Souza
authors: L
authors: L
authors: Farage
authors: T
authors: T
authors: Watanabe
authors: V A
authors: VA
authors: Santos
authors: G G
authors: GG
authors: Cerri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D019540:Area Under Curve; D001281:Atrial Fibrillation / Q000188:drug therapy; D001783:Blood Flow Velocity / Q000502:physiology; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011673:Pulsatile Flow / Q000502:physiology; D012372:ROC Curve; D013961:Thyroid Gland / Q000098:blood supply / Q000000981:diagnostic imaging; D013971:Thyrotoxicosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D018615:Ultrasonography, Doppler, Color; D018616:Ultrasonography, Doppler, Duplex; D014655:Vascular Resistance / Q000502:physiology; D018879:Ventricular Premature Complexes / Q000188:drug therapy
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone